We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App





DiaSorin Launches New LIAISON SARS-CoV-2 Ag High-Throughput Antigen Test in Markets Accepting CE Mark

By LabMedica International staff writers
Posted on 28 Oct 2020
DiaSorin (Saluggia, Italy) has launched its new LIAISON SARS-CoV-2 Ag, a high-throughput antigen test available in markets accepting the CE Mark for quantitative detection of SARS-CoV-2 in symptomatic patients through nasal and nasopharyngeal swabs.

The new high-throughput antigen test uses chemiluminescence immunoassay (CLIA) technology to determine the presence of SARS-CoV-2 Nucleocapsid protein antigen in nasal dry swabs and nasopharyngeal swabs eluted in Universal Transport Media for Virus (UTM/VTM), quantifying the viral load of the infection directly from individuals suspected of COVID-19 by their healthcare provider. More...
The new test is designed for use on the over 8,000 CLIA high-throughput analyzers (LIAISON XL, LIAISON XS and LIAISON) installed in laboratories worldwide, delivering up to 140 results per hour and providing full traceability of collected samples. The test is the first in the market to be run on high-throughput analyzers for COVID-19 detection on symptomatic patients.

In clinical studies, LIAISON SARS-CoV-2 Ag showed, within 10days post onset of symptoms, a 97.1% sensitivity and a 100.0% specificity on nasal swabs and a 94.6% sensitivity and a 99.5% specificity on nasopharyngeal swabs. The LIAISON SARS-CoV-2 Ag is intended as an aid in diagnosing acute COVID-19 infection and will be offered as an alternative solution in cases where molecular PCR testing availability is lacking, in geographies where PCR technology is too expensive and in those cases where traceability of clinical samples needs to be improved. DiaSorin’s manufacturing capacity for LIAISON SARS-CoV-2 Ag is estimated to be up to 10 million tests per month shortly after its launch. The test will be soon available in the US market, following notification to the US Food and Drug Administration. This is the fifth test to be launched by DiaSorin to support laboratories and healthcare systems in containing the spread of SARS-CoV-2 since the beginning of the COVID-19 pandemic worldwide.

“The availability of molecular tests is limited and the need for additional reliable diagnostic tools is on the rise, said Chen Even, Chief Commercial Officer of DiaSorin Group. “This is why we expanded our existing offer for SARS-CoV-2 detection with our new antigen test, allowing safe decentralized sample collection procedure, while maintaining patient sample traceability.”

“The increasing circulation of SARS-CoV-2 is a challenge to healthcare systems and it is driving us to provide innovative solutions to support physicians and laboratories in managing the growing demand in testing volumes,” added Carlo Rosa, CEO of DiaSorin Group. “Our new antigen test is an innovative solution that allows patients to get a quick and reliable response on their infection status, thus supporting the containment of the virus among the population. We are already working on the expansion of the use of our new antigen test to saliva specimens, allowing an even easier, safer and non-invasive sample collection process to be used on a larger amount of individuals.”



Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Collection and Transport System
PurSafe Plus®
New
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The study highlights the potential of cCAFs as a biomarker for early diagnosis and prognosis (H J Woo et al., Analytical Chemistry (2025). DOI: 10.1021/acs.analchem.5c02154)

Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy

Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.